Acelyrin Stock (NASDAQ:SLRN)


ForecastRevenueFinancialsChartTranscripts

Previous Close

$4.72

52W Range

$3.36 - $8.88

50D Avg

$5.41

200D Avg

$5.61

Market Cap

$442.15M

Avg Vol (3M)

$714.74K

Beta

-

Div Yield

-

SLRN Company Profile


Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

135

IPO Date

May 04, 2023

Website

SLRN Performance


SLRN Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-288.41K$-254.68M$-41.79M
Net Income$-381.64K$-250.46M$-41.84M
EBITDA$-288.29K$-254.86M$-41.79M
Basic EPS$-5.43$-12.25$-2.05
Diluted EPS$-5.43$-12.25$-2.05

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 13, 24 | 9:38 PM
Q2 24Aug 13, 24 | 10:32 PM
Q3 23Nov 11, 23 | 3:13 PM